To assess whether the atherogenic cytokines IL-12 and IL-18 vary with cholesterol levels in humans, we measured IL-12 and IL-18 plasma levels in human subjects without known coronary disease and used HMG-CoA reductase inhibitors (statins) of varying potencies to lower cholesterol levels from baseline. Here, IL18 is linked to coronary artery disorder.